Indirubin-3'-oxime reverses bone loss in ovariectomized and hindlimb-unloaded mice via activation of the Wnt/β-catenin signaling

Journal of Bone and Mineral Research

Volumn 29, Issue 5, 2014, Pages 1196-1205

  Zahoor, Muhammad ^a   Cha, Pu Hyeon ^a   Min, Do Sik ^a,b   Choi, Kang Yell ^a  

^a Yonsei University   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

GSK3 inhibitor; indirubin 3' oxime; osteoporosis; ovariectomy; WNT catenin signaling pathway

Indexed keywords

BETA CATENIN; INDIRUBIN; INDIRUBIN 3 OXIME; OXIME DERIVATIVE; UNCLASSIFIED DRUG; WNT PROTEIN; INDIRUBIN-3'-MONOXIME; INDOLE DERIVATIVE; OXIME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; DRUG MECHANISM; FEMALE; HINDLIMB; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; TRABECULAR BONE; ANIMAL; DRUG EFFECTS; HEK293 CELL LINE; IMMOBILIZATION; METABOLISM; PATHOLOGY; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; BONE DENSITY; FEMALE; HEK293 CELLS; HINDLIMB SUSPENSION; HUMANS; INDOLES; MICE; OSTEOPOROSIS; OVARIECTOMY; OXIMES; WNT SIGNALING PATHWAY;

EID: 84899065067     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2147     Document Type: Article

References (43)

1. Cheung AM, Feig DS, Kapral M, Diaz-Granados N, Dodin S,. Canadian Task Force on Preventive Health C. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J. 2004; 170 (11): 1665-7.
2. Sontag A, Krege JH,. First fractures among postmenopausal women with osteoporosis. J Bone Miner Metab. 2010; 28 (4): 485-8.
3. Cummings SR, Melton LJ,. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359 (9319): 1761-7.
4. Mnif H, Koubaa M, Zrig M, Trabelsi R, Abid A,. Elderly patients' mortality and morbidity following trochanteric fracture. A prospective study of 100 cases. Orthop Traumatol Surg Res. 2009; 95 (7): 505-10.
5. Khandewal S, Chandra M, Lo JC,. Clinical characteristics, bone mineral density and non-vertebral osteoporotic fracture outcomes among post-menopausal U.S. South Asian women. Bone. 2012; 51 (6): 1025-8.
6. Sugimoto M, Futaki N, Harada M, Kaku S,. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate. Bone. 2013; 52 (1): 181-8.
7. LeBlanc A, Schneider V, Shackelford L, et al. Bone mineral and lean tissue loss after long duration space flight. J Musculoskelet Neuronal Interact. 2000; 1 (2): 157-60.
8. Armbrecht G, Belavy DL, Backstrom M, et al. Trabecular and cortical bone density and architecture in women after 60 days of bed rest using high-resolution pQCT: WISE 2005. J Bone Miner Res. 2011; 26 (10): 2399-410.
9. Piters E, Boudin E, Van Hul W,. Wnt signaling: a win for bone. Arch Biochem Biophys. 2008; 473 (2): 112-6.
10. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107 (4): 513-23.
11. Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML,. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005; 25 (12): 4946-55.
12. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8 (5): 751-64.
13. Krishnan V, Bryant HU, Macdougald OA,. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116 (5): 1202-9.
14. Clevers H, Nusse R,. Wnt/beta-catenin signaling and disease. Cell. 2012; 149 (6): 1192-205.
15. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM,. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010; 220 (1): 24-33.
16. Hoeppner LH, Secreto FJ, Westendorf JJ,. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009; 13 (4): 485-96.
17. Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA. 2005; 102 (48): 17406-11.
18. Wang YH, Liu Y, Buhl K, Rowe DW,. Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. J Bone Miner Res. 2005; 20 (1): 5-14.
19. Jeong WJ, Yoon J, Park JC, et al. Ras stabilization through aberrant activation of Wnt/beta-catenin signaling promotes intestinal tumorigenesis. Sci Signal. 2012; 5 (219): ra30.
20. Yamaguchi M, Weitzmann MN,. The bone anabolic carotenoid p-hydroxycinnamic acid promotes osteoblast mineralization and suppresses osteoclast differentiation by antagonizing NF-kappaB activation. Int J Mol Med. 2012; 30 (3): 708-12.
21. Garrett IR, Mundy GR,. The role of statins as potential targets for bone formation. Arthritis Res. 2002; 4 (4): 237-40.
22. Sanchez-Fernandez MA, Gallois A, Riedl T, Jurdic P, Hoflack B,. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PloS One. 2008; 3 (10): e3537.
23. Alexander JM, Bab I, Fish S, et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 2001; 16 (9): 1665-73.
24. Wang X, Guo B, Li Q, et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med. 2013; 19 (1): 93-100.
25. Lee SH, Kim B, Oh MJ, et al. Persicaria hydropiper (L.) spach and its flavonoid components, isoquercitrin and isorhamnetin, activate the Wnt/beta-catenin pathway and inhibit adipocyte differentiation of 3T3-L1 cells. Phytother Res. 2011; 25 (11): 1629-35.
26. Ang E, Pavlos NJ, Rea SL, et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol. 2009; 220 (2): 450-9.
27. Finan B, Yang B, Ottaway N, et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat Med. 2012; 18 (12): 1847-56.
28. Davison KS, Siminoski K, Adachi JD, et al. Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum. 2006; 36 (1): 22-31.
29. Visigalli D, Strangio A, Palmieri D, Manduca P,. Hind limb unloading of mice modulates gene expression at the protein and mRNA level in mesenchymal bone cells. BMC Musculoskelet Disord. 2010; 11: 147.
30. Leclerc S, Garnier M, Hoessel R, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors ? J Biol Chem. 2001; 276 (1): 251-60.
31. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999; 1 (1): 60-7.
32. Duensing S, Duensing A, Lee DC, et al. Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene. 2004; 23 (50): 8206-15.
33. Chiara F, Gambalunga A, Sciacovelli M, et al. Chemotherapeutic induction of mitochondrial oxidative stress activates GSK-3alpha/beta and Bax, leading to permeability transition pore opening and tumor cell death. Cell Death Dis. 2012; 3: e444.
34. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG,. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006; 119 (Pt 7): 1283-96.
35. Albers J, Keller J, Baranowsky A, et al. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol. 2013; 200 (4): 537-49.
36. Hughes A, Kleine-Albers J, Helfrich MH, Ralston SH, Rogers MJ,. A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro. Calcif Tissue Int. 2012; 90 (2): 151-62.
37. Wang L, Zhang ZG, Zhang RL, et al. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci. 2006; 26 (22): 5996-6003.
38. Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J,. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem. 2010; 285 (46): 35944-56.
39. Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011; 49 (2): 162-73.
40. Bloomfield SA, Allen MR, Hogan HA, Delp MD,. Site- and compartment-specific changes in bone with hindlimb unloading in mature adult rats. Bone. 2002; 31 (1): 149-57.
41. Kang B, Cheong S, Chaichanasakul T, et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res. 2013; 28 (7): 1631-40.
42. Rosen CJ,. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005; 353 (6): 595-603.
43. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013; 382 (9886): 50-6.